Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
2039 Impact of Diabetes on Patient-Reported Outcomes After Lung Resection: A Prospective Cohort Study Tingting Zhu 1 , Cheng Lei 2 , Qiuling Shi 3 , Wei Dai 4 1 School of Public Health, Chongqing Medical University, Chongqing, Peoples Republic of China, China, 2 Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, Sichuan, China, 3 School of Public Health, Chongqing Medical University
PSG conducted a comprehensive survey of over 200 healthcare payers, including health plans and employers, to better understand their perspectives on the use of GLP-1s for treatment of obesity
The Competitive Landscape: Where Amycretin Fits Let me put amycretin in context against the molecules weve been covering: Retatrutide (Eli Lilly): Triple agonist (GLP-1/GIP/Glucagon)
M., Brennan, A
